SKYLINE-UC Phase 2 Platform Trial in Ulcerative Colitis

Market
0.0%
100%75%50%25%0%Apr 12 • YES 68.8%Apr 12
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
6/1/26
Study Completion
3/1/28
Company
Spyre Therapeutics, Inc.
Ticker
SYRE
Type
Phase 2
Trial Status
Recruiting
Trial Size
645
Volume
$142K
NCT
NCT07012395
Drug Description
This is a Phase 2, multicenter, proof-of-concept platform study in adults with moderately to severely active ulcerative colitis evaluating long-acting antibodies given after IV induction and SC maintenance. Part A is open-label for safety and preliminary efficacy of monotherapies, and Part B is randomized, placebo-controlled, and designed to assess 3 monotherapies plus 3 combination regimens versus placebo.